FI3423087T3 - Syövän vastainen yhdistelmähoito - Google Patents

Syövän vastainen yhdistelmähoito Download PDF

Info

Publication number
FI3423087T3
FI3423087T3 FIEP17709038.8T FI17709038T FI3423087T3 FI 3423087 T3 FI3423087 T3 FI 3423087T3 FI 17709038 T FI17709038 T FI 17709038T FI 3423087 T3 FI3423087 T3 FI 3423087T3
Authority
FI
Finland
Prior art keywords
adjuvant
immunotherapeutic composition
use according
montanide isa
cancer treatment
Prior art date
Application number
FIEP17709038.8T
Other languages
English (en)
Finnish (fi)
Inventor
Mads Andersen
Original Assignee
Io Biotech Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1603805.1A external-priority patent/GB201603805D0/en
Priority claimed from GBGB1610018.2A external-priority patent/GB201610018D0/en
Application filed by Io Biotech Aps filed Critical Io Biotech Aps
Application granted granted Critical
Publication of FI3423087T3 publication Critical patent/FI3423087T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FIEP17709038.8T 2016-03-04 2017-03-03 Syövän vastainen yhdistelmähoito FI3423087T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1603805.1A GB201603805D0 (en) 2016-03-04 2016-03-04 Combination
GBGB1610018.2A GB201610018D0 (en) 2016-06-08 2016-06-08 Combination
PCT/EP2017/055093 WO2017149150A1 (en) 2016-03-04 2017-03-03 Combination therapy against cancer

Publications (1)

Publication Number Publication Date
FI3423087T3 true FI3423087T3 (fi) 2023-12-15

Family

ID=58231605

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP17709038.8T FI3423087T3 (fi) 2016-03-04 2017-03-03 Syövän vastainen yhdistelmähoito

Country Status (13)

Country Link
US (2) US20190343940A1 (https=)
EP (2) EP3423087B1 (https=)
JP (3) JP2019507180A (https=)
DK (1) DK3423087T3 (https=)
ES (1) ES2965009T3 (https=)
FI (1) FI3423087T3 (https=)
HR (1) HRP20240052T1 (https=)
HU (1) HUE064857T2 (https=)
LT (1) LT3423087T (https=)
PL (1) PL3423087T3 (https=)
PT (1) PT3423087T (https=)
SI (1) SI3423087T1 (https=)
WO (1) WO2017149150A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53355A (fr) 2015-05-29 2022-03-16 Agenus Inc Anticorps anti-ctla-4 et leurs procédés d'utilisation
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
HRP20240052T1 (hr) * 2016-03-04 2024-03-29 Io Biotech Aps Kombinirana terapija protiv raka
JP7066696B2 (ja) 2016-10-11 2022-05-13 アジェナス インコーポレイテッド 抗ｌａｇ－３抗体及びその使用方法
DK3551660T5 (da) 2016-12-07 2024-09-02 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
KR20190139216A (ko) 2017-04-28 2019-12-17 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법
US11306144B2 (en) 2017-08-25 2022-04-19 Five Prime Therapeutics, Inc. B7-H4 antibodies and methods of use thereof
WO2019102265A1 (en) * 2017-11-23 2019-05-31 Theraphage Inc. Peptide displaying bacteriophage nanoparticles and related compositions and methods
US20200299401A1 (en) * 2017-11-24 2020-09-24 Io Biotech Aps Enhancement of antibody-dependent cell-mediated cytotoxicity (adcc)
BR112020016986A2 (pt) 2018-02-21 2021-03-02 Five Prime Therapeutics, Inc. formulações de anticorpo contra b7-h4
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
US12589132B2 (en) 2019-02-22 2026-03-31 Five Prime Therapeutics, Inc. CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors
KR102653960B1 (ko) * 2020-07-23 2024-04-03 의료법인 성광의료재단 암 치료를 위한 면역체크포인트 억제제의 병용 요법
MX2023010371A (es) 2021-03-05 2024-02-12 Univ Basel Composiciones para el tratamiento de enfermedades o condiciones asociadas al veb.
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
GB202103673D0 (en) * 2021-03-17 2021-04-28 Io Biotech Aps Combination therapy for cancer
EP4340948A4 (en) * 2021-05-17 2025-03-12 Wisconsin Alumni Research Foundation (WARF) SYNTHETIC PROTEIN TO INDUCE IMMUNE TOLERANCE
US20250213664A1 (en) * 2022-02-18 2025-07-03 Modernatx, Inc. Mrnas encoding checkpoint cancer vaccines and uses thereof
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy
WO2026008017A1 (en) * 2024-07-03 2026-01-08 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
WO2008100562A2 (en) * 2007-02-14 2008-08-21 Medical College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
EP3320912B1 (en) 2008-04-17 2021-03-31 IO BIOTECH ApS Indoleamine 2, 3-dioxygenase based immunotherapy
EP4079319A1 (en) 2011-10-17 2022-10-26 IO Biotech ApS Pd-l1 based immunotherapy
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
SG11201606428UA (en) * 2014-02-04 2016-09-29 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
JP6652557B2 (ja) * 2014-05-30 2020-02-26 ヴェンタナ メディカル システムズ， インク． Ｐｄ−ｌ１について染色された腫瘍組織の改善されたスコア化のための多重アッセイ
HRP20240052T1 (hr) * 2016-03-04 2024-03-29 Io Biotech Aps Kombinirana terapija protiv raka

Also Published As

Publication number Publication date
JP7417645B2 (ja) 2024-01-18
PT3423087T (pt) 2023-12-28
EP4316517A3 (en) 2024-05-29
US20190343940A1 (en) 2019-11-14
HRP20240052T1 (hr) 2024-03-29
WO2017149150A1 (en) 2017-09-08
EP3423087B1 (en) 2023-11-15
DK3423087T3 (da) 2023-12-18
PL3423087T3 (pl) 2024-05-20
EP3423087A1 (en) 2019-01-09
JP7785817B2 (ja) 2025-12-15
US20220257741A1 (en) 2022-08-18
JP2019507180A (ja) 2019-03-14
SI3423087T1 (sl) 2024-03-29
HUE064857T2 (hu) 2024-04-28
EP4316517A2 (en) 2024-02-07
JP2024045180A (ja) 2024-04-02
LT3423087T (lt) 2024-01-25
JP2022068348A (ja) 2022-05-09
ES2965009T3 (es) 2024-04-10

Similar Documents

Publication Publication Date Title
FI3423087T3 (fi) Syövän vastainen yhdistelmähoito
WO2021226436A8 (en) Optimized nucleotide sequences encoding sars-cov-2 antigens
WO2011071574A3 (en) Monoclonal antibodies against glycoprotein of ebola sudan boniface virus
WO2016109546A3 (en) Methods and compositions for prognosis and treatment of cancers
NZ737796A (en) Anti-tau antibodies and methods of use
WO2019226514A3 (en) Molecular gene signatures and methods of using same
EA201892803A1 (ru) Противоопухолевая терапия
EP4233898A3 (en) Influenza mrna vaccines
PH12018501962A1 (en) Stablizied soluble pre-fusion rsv f proteins
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
WO2015143123A3 (en) Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
GEP20247600B (en) B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
PH12019550069A1 (en) Nucleoside phosphate compound and preparation method and use thereof
PH12018502332A1 (en) Stabilized pre-fusion rsv f proteins
WO2019066435A3 (ko) Bcma에 높은 친화도를 가지는 항-bcma 항체 및 이를 포함하는 암 치료용 약학적 조성물
MX2019000725A (es) Composiciones de vacuna para tratamiento de virus zika.
EP4368207A3 (en) Ovarian cancer vaccines
WO2013016278A3 (en) Modulators of antiviral signaling pathways and therapeutic uses thereof
CO6362049A2 (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo
IL274363B2 (en) Use of specific sirna against protein s for the treatment of hemophilia
WO2021019235A3 (en) Hantavirus antigenic composition
MX2017001651A (es) Peptido derivado de urlc10 y vacuna que lo contiene.
WO2017158184A3 (de) Antivirale immuntherapie durch membranrezeptorligation
WO2016036252A3 (en) Hepatitis c virus specific antibody
AR107012A1 (es) ANTICUERPO QUE SE UNE ESPECÍFICAMENTE A ErbB3 Y EL USO DEL MISMO